Compare Ecopetrol SA (EC) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecopetrol SA vs TG Therapeutics Inc — how do they compare? Ecopetrol SA trades at $17.03 (market cap $33.11B), while TG Therapeutics Inc trades at $54.8 (market cap $8.16B). The key difference: Ecopetrol SA is far larger — about 4.1× TG Therapeutics Inc's market cap, and Ecopetrol SA pays a 3.83% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ecopetrol SA for 84 Days and TG Therapeutics Inc for 16 Days on average.
| EC | TGTX | |
|---|---|---|
Market Cap | $33.11B | $8.16B |
Volume | 993,598 | 1,735,121 |
Sector | Energy | Health |
52-Week High | $18.26 | $59.06 |
52-Week Low | $8.61 | $26.94 |
Typical Hold Time | 84 Days | 16 Days |
Enterprise Value | $61.36B | $8.37B |
Dividend Yield | 3.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ecopetrol (EC) trades at $17.07, up 2.65% on the day, but faces a bearish technical signal with recent earnings misses. Revenue declined to $119.69T in 2025, with net income margin at 8.76%, though profitability metrics like ROE (17.67%) remain solid. The company is undergoing senior management changes amid government-led board restructuring, creating uncertainty.
The outlook is mixed: low valuations (P/E 7.97, EV/EBITDA 4) suggest potential upside, but declining revenue, earnings volatility, and political interference pose significant risks. Analyst consensus is cautious with a $16.85 price target below current levels, indicating limited near-term catalysts for substantial growth.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
